Table 2.

A summary of drugs targeting the synthesis and secretion of collagens.

Therapeutics Target	Drug	Mechanism	Cancer Type	Status	Reference
collagen type I	Baicalein	inhibiting collagen type I transcription by alleviating TGF-β1 stimulation	lung cancer, osteosarcoma cells, bladder cancer, breast cancer, pancreatic cancer, cervical cancer, oral cancer	a promising candidate awaiting further testing	[163,164,165]
	Phenylbutyrate, sodium phenylbutyrate	as a weak histone deacetylase inhibitor decreasing collagen type I Alpha 1 mRNA transcription	lung cancer, prostate cancer, liver cancer, breast cancer, ovarian cancer, bladder cancer	a promising candidate awaiting further testing	[166,167,168,169,170,171]
	C9	C9 inhibits collagen production by dissociating laribonucleoprotein domain family member 6 (LARP6) from type I collagen 50′SL RNA	-	awaiting further testing	[172]
	Ethyl 3,4-dihydroxybenzoate (EDHB), 2-(5-carboxythiazol-2-yl) pyridine-5-carboxylic acid (pythiDC)	inhibiting collagen synthesis by inhibiting Prolyl 4-hydroxylases (P4Hs), which is a synthesis and regulatory factor of collagen type I	colorectal cancer, breast cancer	awaiting further testing	[160,173,174]
	Minoxidil	inhibiting collagen synthesis by inhibitor lysyl hydroxylases (LHs), which is a synthesis and regulatory factor of collagen type I	prostate cancer, breast cancer, ovarian cancer	a promising candidate awaiting further testing	[161,162,175,176]
	AK-778	inhibiting collagen synthesis by mitigating the interaction between collagen and HSP47, which is a molecule required for collagen type I maturation.	-	a promising candidate awaiting further testing	[177,178]
	CCT365623	decreasing collagen synthesis by inhibiting lysyl oxidase (LOX), which is a regulatory factor for collagen cross-linking	-	a promising candidate awaiting further testing	[179,180]
collagen type XI	LY2157299	inhibiting collagen XI alpha 1 chain (COL11A1) expression by inhibiting the transforming growth factor beta receptor 1 (TβRI)	ovarian cancer, pancreatic cancer, breast cancer	phase II clinical trial	[181,182,183,184,185]
	SC66	as an Akt inhibitor preventing the transcription of COL11A1	colon cancer, ovarian cancer, bladder cancer, lung cancer	under clinical trials	[182,186,187,188,189]
collagen type XI	AK778 and its cleavage product Col003	disrupted collagen binding with the molecular chaperone HSP47 and inhibited collagen secretion	-	awaiting further clinical studies	[177,182]